The American Journal of Managed Care28 天
FDA Approves Revakinagene Taroretcel for Macular Telangiectasia Type 2
Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based ...
Monthly Prescribing Reference29 天
FDA Approves Encelto for Macular Telangiectasia Type 2
Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...
Healio29 天
FDA approves Encelto for macular telangiectasia type 2
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Encelto is the first FDA-approved treatment for ...
WebMD28 天
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
March 7, 2025 – The FDA has approved a new gene therapy for macular telangiectasia type 2 (MacTel), a rare eye disease that causes vision loss. The approval marks the first and only ...